SOLICITATION NOTICE
B -- Vaccine Adverse Reporting System (VAERS)
- Notice Date
- 9/16/2009
- Notice Type
- Justification and Approval (J&A)
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- Department of Health and Human Services, Centers for Disease Control and Prevention, Procurement and Grants Office (Atlanta), 2920 Brandywine Road, Room 3000, Atlanta, Georgia, 30341-4146
- ZIP Code
- 30341-4146
- Solicitation Number
- 200-2004-10182
- Archive Date
- 9/30/2009
- Point of Contact
- Berta L Biltz, Phone: 770-488-2643
- E-Mail Address
-
boh9@cdc.gov
(boh9@cdc.gov)
- Small Business Set-Aside
- N/A
- Award Number
- 200-2004-10182
- Award Date
- 8/31/2004
- Description
- The Immunization Safety Office's (ISO) mission is to support the goals of the Division of Healthcare Quality Promotion (DHQP) by identifying possible vaccine side effects, conducting epidemiological studies to determine whether a particular adverse event is caused by a specific vaccine, helping to determine appropriate public health responses to vaccine safety concerns, and communicating the benefits and risks of vaccines to the public, media, and healthcare communities. The Vaccine Adverse Event Reporting System (VAERS) is a major component of ISO's vaccine safety monitoring efforts. VAERS is a national passive surveillance program that collects and analyzes reports of adverse events following immunization. VAERS, a public health activity authorized by the National Childhood Vaccine Injury Act of 1986 and administered by CDC in collaboration with the U.S. Food and Drug Administration, serves as an early-warning, post-marketing, signal detection system. The novel H1N1 influenza virus has recently been introduced into the human population. Transmission has subsequently been designated to be at the pandemic level by the World Health Organization. This public health emergency has necessitated the rapid production and deployment of an H1N1 pandemic influenza vaccine. Production is underway with the first round of doses scheduled to be distributed in mid-October 2009. VAERS is a crucial component of CDC's preparedness efforts for this highly-publicized public health emergency. To this end, the VAERS program must be ready to handle a substantial increase in adverse event reporting associated with the release of the H1N1 pandemic influenza vaccine. The VAERS program has established with extended relationship with health care providers and through public promotional efforts throughout the program's 19 year history as a simple and centralized tool for the US public to report vaccine adverse event reports via telephone, voicemail, e-mail, postal mail, fax, etc. We believe that no other source, but Constella Group, LLC in Durham, NC can realistically match the efficiency of the VAERS reporting system or establish comparable infrastructure prior to the imminent release of the H1N1 vaccine. Therefore, a modification to existing contract No. 200-2004-10182 to add this new work is contemplated. The period of performance shall be Sept. 30 2009 to September 29, 2010.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/CDCP/PGOA/200-2004-10182/listing.html)
- Place of Performance
- Address: Atlanta, GA, United States
- Record
- SN01957471-W 20090918/090917000925-a1c5271209a3c1c2a2236ac00ed15852 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |